Do you really gain double the weight back after stopping Ozempic?

What's this video probably claiming?

Based on the caption, @dr.tommymartin is likely leaning into a fear-based narrative: stop Ozempic, gain back twice what you lost. It's a claim that's been circulating since roughly 2022, when rebound weight data from semaglutide trials started getting picked up by mainstream media and filtered through social content creators into something more alarming than the actual numbers support. The "double" framing is the red flag here. It implies that GLP-1 discontinuation doesn't just reverse progress, it actively makes you worse off than when you started. That's a meaningful clinical claim, and it deserves actual scrutiny rather than a viral headline treatment. With 16.4 million views, the downstream anxiety this generates in people currently on semaglutide or considering it is not a small thing.

What does the science actually show?

The most cited evidence comes from the STEP 1 trial extension, published by Wilding et al. in 2022 in Diabetes, Obesity and Metabolism. Participants who lost an average of 17.3% of body weight on 2.4mg weekly semaglutide (Wegovy dosing) regained approximately two-thirds of that weight within one year of stopping. By week 120, mean weight loss from baseline was only 5.6% in the withdrawal group versus 17.4% in those who continued. That is significant rebound, but it is not "double the weight." The body returns toward its original set point. Appetite-regulating hormones like GLP-1, peptide YY, and ghrelin resume their pre-treatment patterns. A 2023 analysis by Aronne et al. in Obesity reinforced this, showing that weight regain after GLP-1 cessation reflects the chronic disease model of obesity, not a drug-induced worsening of metabolism.

Where does the social media noise diverge from clinical reality?

The gap between "you regain most of the weight" and "you gain back double" is not a rounding error. It's the difference between a documented pharmacological reality and a manufactured scare. No peer-reviewed data suggests semaglutide discontinuation causes net weight gain beyond baseline in the average patient. What the data does show is that obesity is a chronic, relapsing condition, and GLP-1 agonists work while you take them, much like antihypertensives work while you take them. The social media version skips that framing entirely because it's less shareable. There's also a conflation problem: some creators blend individual anecdotes, water weight fluctuation in the weeks immediately post-discontinuation, and trial data into a single scary number. The Wilding 2022 data is real. The "double" interpretation is not supported by it.

What should you actually know?

Weight regain after stopping GLP-1 therapy is real, well-documented, and clinically meaningful. It is not punishment or a metabolic trap. It reflects what happens when a medication that reduces appetite, slows gastric emptying, and modulates reward pathways is removed. The SURMOUNT-4 trial (Garvey et al., 2023, JAMA) showed similar patterns with tirzepatide: participants who discontinued after achieving weight loss regained about half their lost weight over 52 weeks, while those who continued lost an additional 5.5%. The practical implication is that these medications may be long-term or indefinite therapies for many patients, similar to how clinicians approach blood pressure or cholesterol management. Anyone stopping GLP-1 therapy should do so in consultation with their prescribing provider, with a realistic plan around diet, activity, and monitoring. Stopping abruptly based on cost or side effects without a plan is where the real clinical risk lives.